FR | EN
IN PERSON PRESENTATION
Dr. Christine Chen
Associate Professor, University of Toronto
Medical Director, Clinical Immune Effector Cell Therapy Program
Division of Medical Oncology and Hematology
Department of Medicine, Princess Margaret Cancer Care
What’s new in Waldenström’s macroglobulinemia (WM) in 2025?
LEARNING OBJECTIVES
Understand Recent Advances –Review the latest clinical trial data and emerging treatment strategies for WM.
Therapeutic Developments –Evaluate novel targeted therapies and their role in disease management.
PersonalizedTreatmentApproaches - Discuss biomarkers, genetic mutations, and prognostic factors
that influence individualized treatment decisions.
Updates in Clinical Guidelines –Summarize recent guideline updates for the treatment of first-line and relapsed/refractory WM.
Emerging Research and Future Directions - Explore ongoing clinical trials and potential future therapeutic approaches in the field of WM.
Tuesday Oct. 21, 2025
HCLM
12:00 - 13:00 EDT
(English)
Room# HN-106
Wednesday Oct. 22, 2025
MUHC
8:30 - 9:30 EDT
(English)
Room# D02. 1312
HMR
12:00 - 13:00 EDT
(English)
Amphitheatre, J.A. Desève
Thursday Oct. 23, 2025
JGH
12:30 - 13:30 EDT
(English)
Room# E-711
CHUM
12:30 - 13:30 EST
(English) Via webcast
Room# C.14.7235
This program has received an educational grant from: AbbVie, AGENCE UNIK, Amgen, Astellas, AstraZeneca, Bayer, BeiGene Bristol Myers Squibb, EISAI, EMD Serono, Forus Therapeutics,
Gilead a Kite Company, GlaxoSmithKline GSK, Ipsen Canada, Janssen, Merck, Pfizer, Roche, Sanofi, Seagen Canada, Servier Taiho Pharma, Takeda, Viatris Canada